key: cord-0766818-yht0enx5
authors: Fertitta, L.; Welfringer, A.; Ouedrani, A.; Polivka, L.; Chhun, S.; Chatenoud, L.; Fourgeaud, J.; Hadj‐Rabia, S.; Temmam, S.; Eloit, M.; Sermet‐Gaudelus,; Bodemer, C.
title: Immunological and virological profile of children with chilblain‐like lesions and SARS‐CoV‐2
date: 2020-10-03
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16972
sha: 9a71e3c30b89f1fdbe8f48f3c2ee6eebc2050d81
doc_id: 766818
cord_uid: yht0enx5

The link between SARS‐CoV‐2 and the reported cutaneous manifestations has not been established. We assessed a possible correlation between the paediatric dermatological manifestations and the biological investigations, using for the first time 3 different SARS‐CoV‐2 tests.

The link between SARS-CoV-2 and the reported cutaneous manifestations has not been established. We assessed a possible correlation between the paediatric dermatological manifestations and the biological investigations, using for the first time 3 different SARS-CoV-2 tests.

From April to June, 2020, minors presenting with skin manifestations and symptoms of COVID-19 themselves or any of first-degree relatives (i.e. fever, influenza-like, respiratory, Ear-Nose-Throat and/or digestive symptoms), were enrolled. Epidemiological and clinical information, description of households and biological results including 3 types of SARS-CoV-2 tests [nasal PCR (systemic symptoms within the past 48 hours), serology (IgG, techniques: Abbott ARCHITECT), and interferon-(IFN-)-ELISPOT-assay] were collected. IFN--ELISPOT-assay, an early (since day 5) qualitative and quantitative analysis, evaluates specific memory T-cells by quantifying the IFN- production after a short-term stimulation with SARS-COV-2 peptide. At least one test among serology and IFN--ELISPOT-assay was performed on patients with chilblains.

Thirty patients (20 boys, average = 9.5 years) representing 28 households were included. Thirtyseven symptomatic first-degree relatives were analyzed. In 23/30 patients (77%) and 14/17 (82%) of chilblains patients, COVID-19 was suspected in at least one first-degree relative and confirmed in 4 and 33% of chilblains patients tested for: TNF-α (range 20-60pg/ml), IL-1 (range 7-280pg/ml), type 1 IFN (range 2-6UI/ml) and IL-6 (range 10-127pg/ml) respectively (Table 1 ). In chilblains, tests were performed in an average of 18 days (5-98) and 21 days (6-51) after skin lesions and systemic manifestations onset respectively.

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Epidemiology of COVID-19 Among Children in China

Cutaneous manifestations in COVID-19: a first perspective

Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Chilblains in children in the setting of COVID-19 pandemic

Chilblain-like lesions in children following suspected COVID-19 infection

Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak

Clinical features of patients infected with

The patients in this manuscript have given written informed consent to the publication of their case details.